The Food and Drug Administration has approved Ozempic ® (semaglutide) to reduce the risk of sustained estimated glomerular filtration rate (eGFR) decline, end-stage kidney disease, and cardiovascular ...

Semaglutide is revolutionizing kidney disease treatment for type 2 diabetes patients. Learn how it works and its potential ...

The latest semaglutide (Ozempic; Novo Nordisk) approval is set to tackle a major need for patients with both type 2 diabetes ...

Recent studies have highlighted the occurrence of true brachial artery aneurysms in patients with a history of AVF ligation and those on immunosuppressive therapy following renal transplantation.

Semaglutide reduced the risk of kidney ... us to more broadly address conditions within cardiovascular-kidney-metabolic syndrome, which affects millions of adults and could have serious ...

The FDA has approved popular antiobesity drug Ozempic to help protect patients with type 2 diabetes from kidney disease.

The FDA has approved a new indication for semaglutide to lower the risk for worsening kidney disease, kidney failure and ...

The U.S. FDA has approved Novo Nordisk's Ozempic for reducing the risk of kidney failure and disease progression, as well as ...

Ozempic has now also been approved by the US Food and Drug Administration to reduce certain risks associated with chronic ...